OBJECTIVE: To evaluate the effect of @entity6383 treatment on @entity650 ( @entity650 ), hyaluronic acid (HA), and soluble interleukin 2 receptor (sIL2R) concentrations in the saliva and serum of @entity1 with primary @entity244 ( @entity244 ). METHODS: Fourteen @entity244 @entity1 treated with @entity6383 200 mg/day for 12 months were investigated in an open prospective study. Clinical parameters of efficacy and routine biochemical and haematological data to assess drug safety and tolerability were determined every three months. Salivary and serum @entity650 , sIL2R, and HA values were determined at study entry, 6 and 12 months, using ELISA and radiometric assays. RESULTS: After @entity6383 treatment, salivary @entity650 concentrations decreased from 13.2 (1.2) to 7.3 (1.1) pg/ml (mean (SEM)) (p < 0.0001). Similarly, salivary HA concentrations were also reduced from 577.8 (120) to 200 (34) ng/ml (mean (SEM) (p < 0.003). Serum @entity650 concentrations decreased from 5.4 (0.6) to 2.9 (0.2) pg/ml (mean (SEM) (p < 0.001), while serum HA concentrations remained unchanged. No change has been detected in salivary or serum sIL2R concentrations after 12 months of treatment with @entity6383 . Treatment also resulted in significant reduction in erythrocyte sedimentation rate, serum gamma globulin, and @entity1851 values while only partial clinical improvement was noted in some @entity1 . A more pronounced decrease of salivary @entity650 and HA levels was found in the two @entity1 in whom a reduction in the swelling of the parotid gland was noted. CONCLUSION: In this open label study of @entity6383 treatment for @entity244 a significant reduction of some salivary inflammatory markers was seen at the end of 12 months. Although during the treatment period only a partial clinical effect could be noted, the findings suggest that a double blind controlled study of @entity6383 in @entity244 is indicated.

XXXX treatment for primary @entity244 : its effect on salivary and serum inflammatory markers.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity650 :: ('3569', 'Gene') :: ['interleukin 6', 'IL6'] @entity6383 :: ('MESH:D006886', 'Chemical') :: ['hydroxychloroquine'] @entity244 :: ('MESH:D014899', 'Disease') :: ["Sj  gren's syndrome", 'SS'] @entity1851 :: ('1401', 'Gene') :: ['C reactive protein']
@entity6383 :: (MESH:D006886,Chemical) :: ['Hydroxychloroquine']
